A Phase I Study of MK-0646 in Patients With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 21 Jun 2017
At a glance
- Drugs Dalotuzumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 02 Sep 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 13 May 2009 Planned end date changed from 1 Jan 2009 to 1 Jun 2009 as reported by ClinicalTrials.gov.
- 13 May 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.